Randomized Phase 2 Study of Tivantinib plus Erlotinib versus Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-small Cell Lung Cancer

BACKGROUND: KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analys...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Gerber, David E., Socinski, Mark A., Neal, Joel W., Wakelee, Heather A., Shirai, Keisuke, Sequist, Lecia V., Rosovsky, Rachel P., Lilenbaum, Rogerio C., Bastos, Bruno R., Huang, Chao, Johnson, Melissa L., Hesketh, Paul J., Subramaniam, Deepa S., Dietrich, Martin F., Chai, Feng, Wang, Yunxia, Kazakin, Julia, Schwartz, Brian, Schiller, Joan H., Brahmer, Julie R., Kelly, Ronan J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836800/
https://ncbi.nlm.nih.gov/pubmed/29496255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2018.01.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados